{"id":"fluticasone-0-005","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin atrophy"},{"rate":null,"effect":"Burning or stinging at application site"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypopigmentation"}]},"_chembl":{"chemblId":"CHEMBL1676","moleculeType":"Small molecule","molecularWeight":"538.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate is a potent topical corticosteroid that reduces inflammation, itching, and other dermatological symptoms by activating glucocorticoid receptors in skin and mucosal tissues. At 0.005% concentration, it is typically formulated for topical application to treat inflammatory skin conditions. The drug works by inhibiting the release of inflammatory mediators and reducing immune cell infiltration at the site of application.","oneSentence":"Fluticasone is a corticosteroid that suppresses local immune and inflammatory responses by binding to glucocorticoid receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:41.518Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory skin conditions (e.g., eczema, dermatitis, psoriasis)"},{"name":"Pruritus and other dermatological inflammatory disorders"}]},"trialDetails":[{"nctId":"NCT05535738","phase":"PHASE2, PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":"Skin Inflammation, Allergic Contact Dermatitis","enrollment":45},{"nctId":"NCT00803218","phase":"","title":"Randomized Study to Compare the Bioavailability of Two Fluticasone Propionate 0.005% Topical Ointments","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2002-11","conditions":"Healthy","enrollment":56},{"nctId":"NCT01134328","phase":"PHASE2","title":"Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2010-05","conditions":"Allergic Conjunctivitis","enrollment":83},{"nctId":"NCT00690105","phase":"PHASE4","title":"Protopic Ointment in Adult Atopic Eczema of the Face","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-02","conditions":"Dermatitis, Atopic","enrollment":577},{"nctId":"NCT00689832","phase":"PHASE4","title":"Protopic Ointment in Children Atopic Eczema","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-02","conditions":"Dermatitis, Atopic","enrollment":487}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Flixovate® 0.005%"],"phase":"marketed","status":"active","brandName":"Fluticasone 0.005%","genericName":"Fluticasone 0.005%","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone 0.005% is a small molecule glucocorticoid receptor agonist, classified as an agonist. It has been studied for various conditions including atopic dermatitis, skin inflammation, and allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}